Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB078 extension in C9ORF72-ALS
NCT04288856Phase 1Terminated
- Sponsor
- Biogen
- Start
- Apr 2020
- Primary completion
- May 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 5
01
Overview
Phase 1, open-label trial of tadnersen in amyotrophic lateral sclerosis (ALS) (4 cohorts), sponsored by Biogen. Primary endpoints: Number of Participants with Adverse Events and Number of Participants with Serious Adverse Events. Started Apr 2020; status: terminated.
02
Drugs
tadnersen
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04288856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04288856.